{"id":1020802,"date":"2026-11-12T20:16:09","date_gmt":"2026-11-13T01:16:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-reports-third-quarter-2026-financial-results-and-recent-business-highlights\/"},"modified":"2026-11-12T20:16:09","modified_gmt":"2026-11-13T01:16:09","slug":"reviva-reports-third-quarter-2026-financial-results-and-recent-business-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-reports-third-quarter-2026-financial-results-and-recent-business-highlights\/","title":{"rendered":"Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights"},"content":{"rendered":"
\n

\n – FDA feedback expected in Q4 2026 on proposed use of new formulation of brilaroxazine in the RECOVER-2 trial and a future NDA submission –<\/em>
\n \n <\/p>\n

\n – U.S. patent office has granted priority examination (Track 1) for the composition of matter patent application filed covering new formulation of brilaroxazine, with potential to extend patent protection through 2046 \u2013<\/em>\n <\/p>\n

\n – Patient enrollment in RECOVER-2 registrational Phase 3 trial expected to begin in 1H 2027, subject to additional financing \u2013 <\/em>
\n \n <\/p>\n

CUPERTINO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the third quarter ended September 30, 2026 and summarized recent business highlights.<\/p>\n

\u201cOur near-term focus is obtaining Food and Drug Administration (FDA) feedback on the proposed use of a new formulation of brilaroxazine and preparing for the next stages of clinical development while managing our capital resources carefully,\u201d said Laxminarayan Bhat, Founder, President, and CEO of Reviva. \u201cWe expect FDA feedback in the fourth quarter of 2026 to inform the use of this formulation in our RECOVER-2 registrational Phase 3 trial and a future New Drug Application (NDA) submission for the treatment of schizophrenia. Following that feedback, we plan to initiate a bioequivalence study to confirm comparability of the new formulation in the first quarter of 2027. We also target initiation of RECOVER-2 patient enrollment in the first half of 2027, subject to receipt of additional financing. In parallel, we have filed a composition of matter patent application for the new formulation of brilaroxazine, with the potential to extend patent protection through 2046. The U.S, patent office has granted priority examination (Track 1) for this patent application. We remain focused on disciplined execution as we advance brilaroxazine as a potentially differentiated treatment option for patients with schizophrenia.\u201d<\/p>\n

\n Clinical Program and Business Highlights<\/strong>\n <\/p>\n